StratifAI joins with MSK iHub Challenge Cohort to advance validation of Polaris™ through access to world-class clinical datasets
Advertisement
StratifAI, the AI precision oncology company behind the Polaris™ platform, today announced its selection for the Memorial Sloan Kettering (MSK) iHub Challenge 2025 Cohort program. This engagement provides StratifAI access to MSK’s extensive clinical datasets and oncology expertise, enabling the company to advance validation of Polaris™, its multimodal AI platform designed to transform routine clinical data into powerful, scalable biomarkers that guide cancer treatment decisions.
Building a new standard in biomarker validation
For decades, biomarker discovery has been limited by high costs, slow processes, and narrow scope. StratifAI overcomes these barriers with Polaris™, a fully digital, multimodal AI platform that transforms routine clinical data, already integral to everyday care, into novel biomarkers that guide treatment decisions. By eliminating the need for costly and specialized inputs, Polaris™ is designed for global scalability and broad access to precision oncology. Through MSK’s resources, StratifAI will further validate Polaris™ on real-world clinical data as it advances toward regulatory approval and guideline inclusion in the EU and US.
Pathways beyond the challenge
The collaboration aims not only to accelerate validation during the Challenge but also hopes to establish a foundation for extended collaboration. StratifAI and MSK hope to build pathways that support ongoing validation of Polaris™ in diverse clinical contexts, strengthening its utility for oncologists worldwide.
"Validating Polaris™ on thousands of patient samples from MSK is a decisive stride toward clinical certification and guideline inclusion across major healthcare systems. Partnering with MSK’s world‑class clinicians and researchers allows us to refine the platform and advance our mission of enabling global access to top-tier cancer care."Omar El NahhasCEO and co-founder of StratifAI
“We are excited to work with StratifAI as part of the MSK iHub Challenge 2025 Cohort. Throughout our competitive evaluation and selection process for this Cohort, it was clear that StratifAI has a focus on technology innovations that can be accelerated to impact through support from MSK.”Rick PengManager, iHub Program and Lead, Digital Ventures in MSK’s Office of Entrepreneurship & Commercialization
Focus on breast cancer recurrence risk
This collaboration builds on StratifAI’s ongoing validation of Polaris™ Breast, a test designed to assess recurrence risk in early-stage breast cancer. By combining exclusive data access partnerships across Europe and the United States, StratifAI is generating the robust clinical evidence required for regulatory approval, reimbursement, and integration into international treatment guidelines.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
The Linde Group and Algenol Biofuels agree to cooperate in CO2 and O2 management for biofuel production from algae
RNA Healer receives around one million euros for the development of a liver fibrosis therapy - MHH project wins start-up funding competition organised by Lower Saxony research incubator Institute for Biomedical Translation Lower Saxony.
Development of novel proteasome inhibitors for treating cancer, inflammatory and autoimmune disorders - Launch of Start-up QLi5 Therapeutics
Biomass for biofuels, biochemicals will more than triple to 3.7 billion tons in 2030
Thianthrenium chemistry allows for reactivity switch of a nucleophilic amino acid into a versatile intermediate - Useful and broadly applicable tool in the field of chemical biology
U.S. Department Of Defense selects Applied Biosystems for development of instrument system to identify infectious diseases
NLS Pharma acquires a portfolio of strategic patents - Critical step in the novel development of a potential non-amphetaminic stimulant for ADHD
